Oscillatory mTOR inhibition and Treg increase in kidney transplantation

Clinical and Experimental Immunology

Volumn 182, Issue 2, 2015, Pages 230-240

  Sabbatini, M ^a   Ruggiero, G ^a   Palatucci, A T ^b,c   Rubino, V ^a   Federico, S ^a   Giovazzino, A ^a,c   Apicella, L ^a   Santopaolo, M ^a   Matarese, G ^e,f   Galgani, M ^d   Terrazzano, G ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Dottorato di Scienze   (Italy)

^c UNIVERSITY OF BASILICATA   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF SALERNO   (Italy)

^f IRCCS MULTIMEDICA   (Italy)

Author keywords

Everolimus; Immunosuppression; Kidney transplants; mTOR

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 17; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; TARGET OF RAPAMYCIN KINASE;

ADULT; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; CADAVER DONOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; NEUTROPHIL COUNT; PRIORITY JOURNAL; PRURITUS; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANTAGONISTS AND INHIBITORS; BLOOD; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; PROCEDURES; TIME FACTOR;

ADULT; CALCINEURIN INHIBITORS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; EVEROLIMUS; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84944155213     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12669     Document Type: Article

References (48)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725-38.
2. Sahin S, Gürkan A, Uyar M et al. Conversion to proliferation signal inhibitors-based immuno-suppressive regimen in kidney transplantation: to whom and when? Transplant Proc 2011; 43:837-40.
3. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30:964-74.
4. Meier-Kriesche H, Schold J, Srinivas T, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-83.
5. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22:2107-18.
6. Ekberg H, Tedesco-Silvia H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562-75.
7. Stallone G, Infante B, Schena A et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16:3755-62.
8. Holdaas H, Bentdal O, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008; 22:366-71.
9. Hernández D, Martínez D, Gutiérrez E et al. Clinical evidence on the use of anti-mTOR drugs in renal transplantation. Nefrologia 2011; 31:27-34.
10. Wullschleger S, Loewith R, Hall MN. TOR signalling in growth and metabolism. Cell 2006; 124:471-84.
11. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172:603-6.
12. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003; 81:331-71.
13. Sakaguchi S, On M, Setoguchi R et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212:8-27.
14. Shevach EM, Di Paolo RA, Andersson J, Zhaom DM, Stephens GL, Thornton AM. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 2006; 212:60-73.
15. Delgoffe GM, Pollizzi KN, Waickman AT et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011; 12:295-303.
16. Lee K, Gudapati P, Dragovic S et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010; 32:743-53.
17. Delgoffe GM, Kole TP, Zheng Y et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-44.
18. Procaccini C, De Rosa V, Galgani M et al. Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J Immunol 2012; 189:2941-53.
19. Procaccini C, De Rosa V, Galgani M et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 2010; 33:929-41.
20. Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8+ T cell differentiation. Immunity 2012; 36:374-87.
21. O'Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 2010; 3:65-79.
22. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64:36-42.
23. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012; 18:2766-77.
24. Eyre TA, Collins GP, Goldstone AH, Cwynarski K. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. Br J Haematol 2014; 166:336-51.
25. Lebwohl D, Anak O, Sahmoud T et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann NY Acad Sci 2013; 1291:14-32.
26. Budde K, Becker T, Arns W et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.Lancet 2011; 377:837-47.
27. Alfinito F, Ruggiero G, Sica M et al. Eculizumab treatment modifies the immune profile of PNH patients. Immunobiology 2012; 217:698-703.
28. Alfinito F, Sica M, Luciano L et al. Immune dysregulation and dyserythropoiesis in the myelodysplastic sindrome. Br J Haematol 2010; 148:90-8.
29. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336.
30. Duchrow M, Schluter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki67. Cell Prolif 1996; 29:1-12.
31. Fang Y, Park IH, Wu AL et al. PLD1 regulates mTOR signaling and mediates CDC42 activation of S6K1. Curr Biol 2003; 13:2037-44.
32. Sun Y, Chen J. mTOR signaling: PLD takes center stage. Cell Cycle 2008; 7:3118-23.
33. Berven LA, Willard FS, Crouch MF. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004; 296:183-95.
34. Vitiello D, Neagoe PE, Sirois MG, White M. Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation. Cell Mol Immunol 2015; 12:40-52.
35. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11:519-31.
36. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14:562-8.
37. Morita K, Miura M, Paolone DR et al. Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. J Immunol 2001; 167:2979-84.
38. Kao J, Kobashigawa J, Fishbein MC et al. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 2003; 107:1958-61.
39. Li Q, Rao RR, Araki K et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 2011; 34:541-53.
40. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000; 192:549-56.
41. Ernst B, Lee DS, Chang JM, Sprent J, Surh CD. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 1999; 11:173-81.
42. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 1999; 11:183-190.
43. Zeng H, Chi H. mTOR and lymphocyte metabolism. Curr Opin Immunol 2013; 25:347-55.
44. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol 2014; 14:435-46.
45. Kyoung WK, Byung HC, Bo-Mi K, Mi-La C, Chul WY. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology 2014; 144:68-78.
46. Wu T, Zhang L, Xu K et al. Immunosuppressive drugs on inducing Ag-specific CD4+CD25+Foxp3+ Treg cells during immune response in vivo. Transpl Immunol 2012; 27:30-8.
47. Lim DG, Koo SK, Park YH et al. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. Transplantation 2010; 89:928-36.
48. Demirkiran A, Sewgobind VD, van derWeijde J et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation 2009; 87:1062-68.